ClinicalTrials.Veeva

Menu

Analysis of the Resistance and Sensitivity Mechanisms to Teclistamab by Focusing on Single Immune Cell Examination (ResisTec)

T

Toulouse University Hospital

Status

Not yet enrolling

Conditions

Multiple Myeloma

Treatments

Other: Bone marrow sampling

Study type

Interventional

Funder types

Other

Identifiers

NCT05945524
RC31/23/0278

Details and patient eligibility

About

The aim of this study is to discover the immune and oncogenomic features that distinguish patients who respond to teclistamab from patients who are primarily resistant. Moreover, phenotypic and genotypic characteristics that occur with secondary resistance to teclistamab will be analyzed.

Enrollment

100 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • With multiple myeloma
  • Who receive Teclistamab
  • Consent form signed

Exclusion criteria

  • Patient under legal protection

Trial design

Primary purpose

Other

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

100 participants in 1 patient group

Analysis of bone marrow
Experimental group
Description:
Analysis of bone marrow in patients initiated treatment by Teclistamab for 18 cycles
Treatment:
Other: Bone marrow sampling

Trial contacts and locations

0

Loading...

Central trial contact

Hervé AVET LOISEAU, MD, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems